Article
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2017
Ma Cynthia X, Bose Ron, Gao Feng, Freedman Rachel A, Telli Melinda L, Kimmick Gretchen, Winer Eric, Naughton Michael, Goetz Matthew P, Russell Christy, Tripathy Debu, Cobleigh Melody, Forero Andres, Pluard Timothy J, Anders Carey, Niravath Polly Ann, Thomas Shana, Anderson Jill, Bumb Caroline, Banks Kimberly C, Lanman Richard B, Bryce Richard, Lalani Alshad S, Pfeifer John, Hayes Daniel F, Pegram Mark, Blackwell Kimberly, Bedard Philippe L, Al-Kateb Hussam, Ellis Matthew J C
Abstract excerpt
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) HER2mut detection.Experimental...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.